ERBB2 and cancer: The previous in vivo experiment (11) proved that the 211At-trastuzumab concentrated in the tumor (i.e., HER2 distribution) correlates to the double-strand break distribution by the γ-H2AX observation, indicating that the 211At-trastuzumab concentration causes the lethal damage to cancer cells.